Ask AI

From Subtle Signs to Serious Impact: Tardive Dyskinesia Nuances in Geriatrics

Video
This activity is available for 1.00 CME/CE credit(s).

Released: October 12, 2026

Expiration: October 11, 2027

See Activity Collection

Tardive dyskinesia is underrecognized in older adults, despite its potential to affect daily activities, fall risk, communication, and quality of life. This on-demand webcast examines risk factors, practical strategies for recognizing and assessing tardive dyskinesia in geriatric and long-term care settings, differential diagnosis, and evidence-based treatment with VMAT2 inhibitors to support earlier identification and individualized management to improve patient care.

TD in Geriatrics

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people at risk for developing TD (ie, treated with antipsychotics) do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of these nonantipsychotic medications have a risk of tardive dyskinesia due to D2 receptor antagonism?

4.

Which would be the most useful technique to assess for tardive dyskinesia in a LTC patient with dementia who is not able to follow verbal instructions for a movement exam?

5.

You wish to initiate VMAT2 inhibitor treatment for a patient with TD who has difficulty swallowing pills. What recommendations should you follow for non-pill administration options?